Novozymes prevails in patent trial against Danisco
Kristian Merser, general counsel in Novozymes states: "We are very pleased with the decision but we are obviously annoyed by the harm the patent infringement has caused on our market for biofuel enzymes. It´s very satisfactory that the court agreed that our patent is valid and has been infringed - considering the large amount of resources we use on research, development and patenting."
Danisco announced that the company has withdrawn the product that infringed Novozymes' patent (Spezyme(R) Ethyl) from the market. The size of the damages will be decided in the fall. Novozymes has claimed several million US dollars in damages for loss of profits.
Most read news
Other news from the department politics & laws
Get the life science industry in your inbox
By submitting this form you agree that LUMITOS AG will send you the newsletter(s) selected above by email. Your data will not be passed on to third parties. Your data will be stored and processed in accordance with our data protection regulations. LUMITOS may contact you by email for the purpose of advertising or market and opinion surveys. You can revoke your consent at any time without giving reasons to LUMITOS AG, Ernst-Augustin-Str. 2, 12489 Berlin, Germany or by e-mail at revoke@lumitos.com with effect for the future. In addition, each email contains a link to unsubscribe from the corresponding newsletter.